SickKids Researchers Repurpose Leukemia Medication to Selectively Target and Eliminate Damaged Fat Cells in Obesity Models

SickKids researchers find that low-dose homoharringtonine selectively kills aged fat cells, reducing inflammation and improving metabolism in preclinical models.

By: AXL Media

Published: Apr 1, 2026, 5:35 AM EDT

Source: Information for this report was sourced from The Hospital for Sick Children

The Shift Toward Cellular Dysfunction in Obesity

Medical understanding of metabolic conditions, such as type 2 diabetes, is moving away from a simple focus on excess weight and toward the underlying health of fat tissue. According to Dr. Hoon-Ki Sung, a Senior Scientist at SickKids, chronic inflammation and tissue dysfunction are the true drivers of these diseases. As fat tissue expands or ages, it accumulates senescent cells—damaged "zombie" cells that no longer function correctly but refuse to die. These cells impair the tissue's ability to regenerate, eventually leading to systemic insulin resistance and other serious metabolic failures.

Repurposing Homoharringtonine for Metabolic Health

In a search for a solution to this cellular buildup, researchers screened over 2,000 clinically approved compounds to find one that could kill damaged cells while leaving healthy ones intact. The team discovered that homoharringtonine (HHT), a drug originally approved for treating leukemia, possessed a potent and selective therapeutic effect when administered at low doses. In preclinical models of obese and aging mice, HHT successfully eliminated the burden of senescent cells, resulting in a marked reduction in inflammation and a restoration of normal fat tissue function.

Unexpected Preservation of Muscle and Lean Mass

One of the most striking findings of the study was that HHT treatment did not cause the muscle wasting often associated with intensive medical therapies. Instead, the preclinical models maintained their muscle mass and function while becoming leaner. Dr. Sung expressed surprise at this result, noting that the drug appeared to selectively target the "bad" fat without negatively impacting the "good" lean tissue. This precision suggests that HHT could overcome the limitations of current weight-loss strategies that often result in the simultaneous loss of vital muscle tissue.